We show that overexpression of these GRPR targets is restricted to prostate carcinomas harbouring ERG and/or ETV1 rearrangements [13], establishing their potential as therapeutic targets for these particular molecular subsets of the disease. The gene discussed is GRPR; the disease is prostate carcinoma.